If a clinician has mentioned Zepbound (tirzepatide) as part of a weight management plan, you may have seen it offered in two different ways: a pre-filled pen or a vial used with a separate syringe. The drug inside is the same. What differs is how it's packaged, how it's injected, and in some cases, how it's paid for. Here's what the manufacturer's own prescribing information says about each, what the evidence actually covers, and what's worth asking before you start.
The short answer
Zepbound's single-dose pen and single-dose vial contain the same fixed dose of the same formulation — not a variable amount decided at the time of injection. The pen delivers that dose through a self-contained, pre-filled auto-injector with a built-in needle. The vial delivers the identical dose, but you draw it into a separate syringe and needle before injecting. Neither presentation requires mixing, reconstituting, or calculating the dose yourself — the amount in a given pen or vial is fixed by its labeled strength.
What's actually different between them
According to Eli Lilly's prescribing and medical information, the single-dose vial and single-dose pen:
- Share the same formulation — identical active ingredient, excipients, excipient concentrations, drug concentration, dose strengths, injection volume, and route of administration.
- Are both single-use and preservative-free — each pen or vial is meant for one injection, then discarded.
- Differ in delivery hardware — the pen's needle is self-contained, and the device is ready to use; the vial requires a separate syringe and needle, an alcohol swab, and a sharps container, and the dose has to be drawn up correctly before injecting.
- Differ in how they're typically obtained — single-dose pens can go through standard insurance or commercial coverage, with a manufacturer savings card for eligible patients. As of this writing, single-dose vials are sold exclusively through Lilly's self-pay channel (LillyDirect), regardless of insurance status, at a published monthly price that varies by dose strength and program terms.
Both presentations are available across the full range of approved Zepbound doses (2.5 mg through 15 mg), though pricing and program details for the vial are specific to Lilly's self-pay program and have changed more than once since the vial's 2024 launch — worth confirming at the source before relying on any specific number.
What the evidence does — and doesn't — establish
Zepbound's clinical efficacy was established in trials that used the single-dose pen. The single-dose vial wasn't tested in its own outcomes trial; instead, its approval rests on showing it has the same formulation, analytical specifications, and acceptance criteria as the pen that was tested. In plain terms: the regulatory case for the vial is “this is chemically and physically the same product in different packaging,” not “this delivery method was tested head-to-head against the pen for outcomes like weight loss or missed-dose rates.”
That's a meaningful limit if you're trying to decide between the two based on effectiveness — the published evidence doesn't really let you compare them that way. What it does support is that a correctly measured and administered dose from either presentation delivers the same amount of medication.
A comparison worksheet for your next appointment
Rather than guessing which format fits your situation, consider bringing these questions to your prescriber:
- Coverage and cost: Does my insurance cover the pen, and would the vial's self-pay price be higher or lower for my prescribed dose?
- Administration comfort: Am I comfortable drawing a dose from a vial with a syringe, or would a ready-to-use pen reduce the chance of a measurement error?
- Storage and travel: How should I store whichever presentation I'm using, and does that change if I'm traveling?
- Supplies: If I use the vial, what exactly do I need on hand (syringe type, needle gauge, sharps disposal) and where do I get them?
- What's unresolved: Is there anything about my specific health history where the delivery method itself — not just the drug — matters?
One more distinction worth making
Tirzepatide, the active ingredient in Zepbound, is also sold under a different brand name for type 2 diabetes. Zepbound itself is FDA-approved for chronic weight management in adults with obesity (or overweight with a weight-related condition) and for moderate-to-severe obstructive sleep apnea in adults with obesity — not for diabetes. If you've seen dosing or packaging information under the other brand name, don't assume it applies directly to Zepbound; confirm with your prescriber which product and indication apply to you.
What this guide is — and isn't
This is meant to help you ask better questions, not to replace a conversation with your prescriber. We haven't tested either presentation ourselves, and nothing here is a recommendation for one format over the other. Pricing, available doses, and program terms for the self-pay vial option have changed more than once in the past year and may change again — treat any dollar figure or dose list here as a starting point to verify, not a locked-in fact.
For general background, the NIDDK's overview of weight management is a reasonable starting point for further reading.